Key facts
- Emboline’s last known valuation is $151.4M (Jun 2021).
- It has raised $102.0M across 2 recorded rounds; the latest was Later Stage VC ($55.4M) in May 2021.
- Notable investors include Western Technology Investment, ShangBay Capital, SV Tech Ventures, Matrix Capital Management, GAM Investments — 12 tracked in total.
- Emboline has filed 3 Form Ds with the SEC since 2020, most recently Jun 2021 ($55.4M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Emboline
Funding rounds
2 roundsAbout Emboline
Developer of an embolic protection catheter designed to offer embolic protection during percutaneous heart valve repair and replacement procedures. The company's catheter protects the arterial bed and circumferentially conforms to a wide range of patient anatomies, while the expandable access port accommodates a wide range of procedural devices, enabling medical providers to provide complete protection of the brain and other critical organs by capturing and removing emboli produced during the procedure.
- Sector
- Healthcare
- HQ
- Santa Cruz, CA, United States
- Founded
- 2011
- Employees
- 23
- Website
- emboline.com/
- Ownership
- Privately Held (backing)
Emboline doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Emboline shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Emboline in its N-PORT filings yet. We sweep new filings monthly.